Short-Chain RNA Biomarker Detection in Extracellular Vesicles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting neurodegenerative diseases are invasive, costly, and require complex analysis, making them less accessible and practical for widespread use.
Innovation Solution
A method involving the measurement of the total amount of short-chain RNA per extracellular vesicle in a body fluid sample to determine if a subject is affected by a neurodegenerative disease, compared to a healthy individual.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If imaging tests (MRI, FDG-PET, DAT scan) are used for neurodegenerative disease detection, then measurement accuracy is improved, but device complexity and invasiveness increase
Solution Approach 1:
The invention extracts and measures specific biomarkers (short-chain RNA, proteins, metabolites) from extracellular vesicles in body fluids as diagnostic indicators. By focusing on these extracted molecular markers rather than requiring complex imaging systems, the method achieves disease detection through simpler biochemical analysis while maintaining diagnostic accuracy.
Solution Approach 2:
The invention uses extracellular vesicles as intermediary carriers that transport disease-specific biomarkers from neural tissues to body fluids. These vesicles serve as natural mediators, allowing indirect detection of neurodegenerative diseases through accessible body fluid samples rather than direct brain imaging, thereby simplifying the diagnostic system.
2Reliability
If imaging tests are used for neurodegenerative disease detection, then detection capability is improved, but ease of operation deteriorates
Solution Approach 1:
The method extracts and quantifies specific biomolecules (short-chain RNA, proteins, metabolites) from extracellular vesicles in body fluids. This extraction approach enables reliable disease detection through straightforward biochemical measurements that can be performed in routine laboratories, greatly improving ease of operation compared to complex imaging procedures.
Solution Approach 2:
The invention employs simple, cost-effective biochemical assays using commercially available reagents and equipment for measuring RNA, proteins, and metabolites. These disposable-like single-use testing approaches eliminate the need for expensive, specialized imaging facilities while maintaining reliable detection capability.
3Measurement precision
If complex biomarker analysis is performed, then measurement precision is improved, but ease of manufacture deteriorates
Solution Approach 1:
The invention segments the diagnostic approach by measuring multiple different biomarker types (short-chain RNA, proteins, metabolites) from extracellular vesicles. This segmentation allows each biomarker to be measured using simple, standardized biochemical techniques, avoiding the need for complex integrated analysis algorithms while maintaining high measurement precision through multi-parameter assessment.
Solution Approach 2:
The invention changes the measured parameters from complex imaging data requiring advanced algorithms to fundamental biochemical parameters (RNA concentration, protein levels, metabolite amounts) that can be measured with simple quantitative assays. This parameter transformation maintains detection accuracy while dramatically simplifying the manufacturing and implementation of the diagnostic method.
Data Source
AI summary
Disclosed is a method that enables detection of whether or not a subject is affected by a neurodegenerative disease, which method is simpler and more effective than conventional methods. This method includes the steps of: (a) preparing an extracellular vesicle fraction from a body fluid sample of the subject; (b) counting the number of extracellular vesicles contained in the extracellular vesicle fraction obtained in Step (a), to obtain the number of the extracellular vesicles; (c) measuring the total amount of short-chain RNA contained in all extracellular vesicles counted in Step (b), to obtain the total amount of short-chain RNA per extracellular vesicle; and (d) judging the subject as being affected by the neurodegenerative disease in a case where the total amount of short-chain RNA per extracellular vesicle obtained in Step (c) is larger than a total amount of short-chain RNA per extracellular vesicle obtained from a body fluid sample of a healthy individual.